sBCMA Plasma Quantification via Hybrid Mass Spectrometry

CellCarta’s poster presents a high-throughput hybrid immunoaffinity LC-MRM based method for quantifying soluble BCMA (sBCMA) in human plasma.

The study demonstrates that sBCMA, a marker for multiple myeloma, can be precisely measured using this method, which overcomes interferences from ligands and therapeutic antibodies. The assay shows high sensitivity, a broad linear range, and robustness against interferences, making it suitable for clinical studies and monitoring treatment response in multiple myeloma patients

Quantification of sBCMA in Human Plasma using a High-ThroughputHybrid IP-MRM Based Mass Spectrometry Workflow, As presented at ASMS 2022